Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
about
A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderlyCurrent and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatmentsLinaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic ConstipationPhysiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.The safety of novel drugs used to treat irritable bowel syndrome.Phase II drugs under clinical investigation for the treatment of chronic constipation.Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.Novel pharmacological therapies for irritable bowel syndrome.Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-mediated Pathway
P2860
Q26824999-D9E60775-1057-4601-A46B-82030DCEF93DQ34478089-752EB525-50FD-4647-8D1E-5C55940C0D86Q34660338-DF457C29-AD1A-48C3-9F97-B2B5AA529095Q36801233-4419109F-B711-41E6-BD00-D64AD268B12CQ37491434-70A83B83-1B72-4FF9-A20B-9069579F0BDCQ38086870-2BA131A8-26FE-4C5F-A137-DAEDC808B213Q38175457-EB681A57-D787-495B-BB51-F0DF794EFD61Q38199522-8B11A54F-8E97-4D25-88F2-21A9F49D35A9Q38222819-60318A37-9E10-4A1A-8861-7411D20C7E58Q38604426-7835F40F-C41E-4DD2-9427-09D0744DF842Q38747166-2A43400F-7482-487C-819A-B75863C23F6FQ39051851-4ED6DFB4-21DE-4CD1-BC04-B19A49A4B304Q41784614-5EFF5AA1-BA5A-4855-A9EA-B87556D8ED83
P2860
Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Safety evaluation of lubipros ...... and irritable bowel syndrome.
@en
type
label
Safety evaluation of lubipros ...... and irritable bowel syndrome.
@en
prefLabel
Safety evaluation of lubipros ...... and irritable bowel syndrome.
@en
P2860
P1476
Safety evaluation of lubipros ...... and irritable bowel syndrome.
@en
P2093
Satish S C Rao
Sherman M Chamberlain
P2860
P304
P356
10.1517/14740338.2012.708732
P407
P577
2012-07-27T00:00:00Z